Last reviewed · How we verify

Mycophenolate mofetil,methotrexate

Assistance Publique - Hôpitaux de Paris · FDA-approved active Small molecule ✓ Verified May 2026 Quality 2/100

Mycophenolate mofetil,methotrexate is a Small molecule drug developed by Assistance Publique - Hôpitaux de Paris. It is currently FDA-approved.

Mycophenolate mofetil is a small molecule inhibitor of inosine-5'-monophosphate dehydrogenase (IMPDH). It is used to treat various hematologic malignancies, including multiple myeloma, lymphocytic leukemia, lymphoma, acute leukemia, and chronic myelogenous leukemia, as indicated by clinical trials on ClinicalTrials.gov.

At a glance

Generic nameMycophenolate mofetil,methotrexate
SponsorAssistance Publique - Hôpitaux de Paris
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Mycophenolate mofetil,methotrexate

What is Mycophenolate mofetil,methotrexate?

Mycophenolate mofetil,methotrexate is a Small molecule drug developed by Assistance Publique - Hôpitaux de Paris.

Who makes Mycophenolate mofetil,methotrexate?

Mycophenolate mofetil,methotrexate is developed and marketed by Assistance Publique - Hôpitaux de Paris (see full Assistance Publique - Hôpitaux de Paris pipeline at /company/assistance-publique-h-pitaux-de-paris).

What development phase is Mycophenolate mofetil,methotrexate in?

Mycophenolate mofetil,methotrexate is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing